Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2025)

Kiniksa Pharmaceuticals International's EBITDA Margin history spans 5 years, with the latest figure at 7.09% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1444.0% year-over-year to 7.09%; the TTM value through Dec 2025 reached 8.73%, up 1897.0%, while the annual FY2025 figure was 8.73%, 1897.0% up from the prior year.
  • EBITDA Margin reached 7.09% in Q4 2025 per KNSA's latest filing, down from 10.14% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 226.07% in Q3 2022 to a low of 538.88% in Q2 2021.
  • Average EBITDA Margin over 5 years is 48.42%, with a median of 7.35% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: soared 47920bps in 2022, then crashed -24675bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 193.94% in 2021, then soared by 98bps to 3.09% in 2022, then surged by 1081bps to 30.27% in 2023, then plummeted by -124bps to 7.35% in 2024, then skyrocketed by 196bps to 7.09% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EBITDA Margin are 7.09% (Q4 2025), 10.14% (Q3 2025), and 11.44% (Q2 2025).